Printer Friendly

COMPANY INFORMATION
BELLUS Health Inc. 275 boul Armand-Frappier Laval, QC H7V 4A7 Tel: (450) 680-4500 Toll-free: (877) 680-4500 Fax: (450) 680-4501 Contact Name Michelle Stein Industry Biotechnology		Key Executives Roberto Bellini, CEO François Desjardins, v-p, fin. Develops and commercializes therapeutic treatments targeting Amyloid A (AA) amyloidosis, Alzheimer's disease, Type II diabetes and certain features of metabolic syndrome. Through wholly owned OVOS Natural Health Inc., the company conducts research and develops and commercializes branded nutraceuticals that target condition-specific needs of consumers, with a focus primarily on memory and cognition.
FP ADVISOR COVERAGE BELLUS Health Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Investor Reports • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/BLU $0.22 $0.46 $0.16 n.a. n.a. n.a. 1.16 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 94,150 n.a. US$-0.24 Sept. 30/09 -47.55% -77.52% -60.96% $23,452
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 US$000s US$000s $000s Operating revenue 584 1,515 2,389 Net income (48,095) (81,486) (75,387) Total assets 26,416 78,431 83,211 US$ US$ $ Earnings per share* (0.97) (1.85) (1.95)   * Common
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09 Sept. 30/08 US$000s US$000s Operating revenue 452 697 Net income (14,259) (52,800) US$ US$ Earnings per share (0.37) (1.07)

COMPANY NEWS

Results for 'BELLUS Health Inc.' from past 30 days: No hits. (Links are to articles.)